Clinical Trial VICCGI1370

Title

A Phase 1b Dose Escalation Study of Vantictumab (OMP-18R5) in Combination with Nab-Paclitaxel and Gemcitabine in Patients with Previously Untreated Stage IV Pancreatic Cancer

Principal Investigator(s)

Jordan Berlin

Details

  • Protocol No. VICCGI1370
  • Open Date: 12/30/2013
  • Staging: Phase I
  • Age Group: Adults
  • Scope: National
  • Objective: To evaluate the safety and tolerability of vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated Stage IV pancreatic cancer To identify dose-limiting toxicities (DLTs) and estimate the maximum tolerated dose of vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated Stage IV pancreatic cancer To identify a recommended Phase 2 dose for vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated Stage IV pancreatic cancer
  • Disease Sites: Pancreatic
  • Therapies: Chemotherapy - cytotoxic; Molecular Targeted Agents / Immunotherapy / Biologics
  • Drugs: Gemcitabine; Nab-paclitaxel; Vantictumab
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT02005315
  • Secondary Protocol No: 18R5-003

Description

Eligibility

Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.